Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Endometriosis, ovarian disorders, uterine disorders, tubal disorders, and hormonal disorders are the major cause of female infertility, whereas male infertility is caused by azoospermia, varicocele, ejaculation disorders, and erectile dysfunction.
A sample of this report is available upon request @ https://www.coherentmarketinsights.com/insight/request-sample/4122
Statistics:
The global infertility drugs and devices market is estimated to account for US$ 9,702.4 Mn in terms of value by the end of 2019.
Global Infertility Drugs and Devices Market: Drivers
Increasing prevalence of erectile dysfunction is expected to propel growth of the global infertility drugs and devices market over the forecast period. For instance, according to the study ‘The Global Prevalence of Erectile Dysfunction: A Review’, published in BJUI International, in July 2019, the global prevalence of erectile dysfunction was 3–76.5%.
Global Infertility Drugs and Devices Market: Opportunities
R&D in diagnosis of infertility is expected to offer lucrative growth opportunities for players in the global infertility drugs and devices market. For instance, in May 2018, DiaSorin S.p.A launched LIAISON test for the measurement of sex hormone-binding globulin in human serum and plasma for the diagnosis of infertility, decreased libido and erectile dysfunction in men and polycystic ovarian syndrome in women.
Read Press Release: https://www.coherentmarketinsights.com/press-release/infertility-drugs-and-devices-market-3382
Global Infertility Drugs and Devices Market: Restraints
Narrowing of insurance coverage for erectile dysfunction treatment is expected to limit growth of the market. A person with a documented medical condition responsible for the cause of erectile dysfunction may incur insurance benefits. However, sex therapies and medications that have not been approved by the FDA have not been covered under insurance.
Key Takeaways:
The global infertility drugs and devices market was valued at US$ 6,096.7 Mn in 2019 and is forecast to reach a value of US$ 9,702.4 Mn by 2027 at a CAGR of 5.8% between 2020 and 2027. Increasing prevalence of erectile dysfunction is expected to propel growth of the global infertility drugs and devices market over the forecast period.
Infertility Drugs segment held dominant position in the global infertility drugs and devices market in 2019, accounting for 77.0% share in terms of value, increasing prevalence of erectile dysfunction is expected to assist the segment growth
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/4122
Market Trends
Decreasing birth rate is expected to propel growth of the global infertility drugs and devices market. For instance, according to National Vital Statistics System, the provisional number of births for the U.S. in 2018 was 3,788,235, registering a decrease of 2% from 2017 and the lowest number of births in 32 years.
The adoption of Machine Learning and Artificial Intelligence (AI) in diagnosis of infertility is on the rise. For instance, in May 2020, researchers from Peking University, China, proposed a specialized convolutional neural network architecture to accurately classify human sperm heads based on sperm images.
Global Infertility Drugs and Devices Market: Competitive Landscape
Major players operating in the global infertility drugs and devices market include, Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., Pfizer, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc. Mylan Pharmaceuticals Inc., Ferring Pharmaceuticals, Cipla Ltd, Aspargo Laboratories, Inc., Aurobindo Pharma Ltd., Lupin Limited, Novartis International AG, Daré Bioscience, Inc., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, and Dr. Reddys Laboratories Ltd.
Global Infertility Drugs and Devices Market: Key Developments
May 2020: Ferring Pharmaceuticals announced that MEGASET-HR, a trial comparing Menopur (menotropins for injection indicated for the development of multiple follicles and pregnancy in ovulatory patients participating in an Assisted Reproductive Technology (ART) program) to recombinant follicle-stimulating hormone met its primary endpoint, with Menopur-treated patients experiencing a 35.5% OPR per cycle start after fresh transfer.
May 2020: Aspargo Laboratories, Inc. announced the results of its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food & Drug Administration, where the FDA addressed Aspargo’s questions and provided guidance on the company’s Sildenafil Oral Spray for the treatment of erectile dysfunction
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/4122
Segmentation
Scope of the report
- Global Infertility Drugs and Devices Market, By Type:
- Infertility Drugs
- Clomiphene citrate
- Sex hormones
- Gonadotropins
- Bromocriptine
- Cabergoline
- Imipramine
- Letrozole
- Metformin
- Infertility Devices
- Equipment
- Accessories
- Infertility Drugs
- Global Infertility Drugs and Devices Market, By Gender:
- Male
- Female
- Global Infertility Drugs and Devices Market, By Region:
- North America
- By Type:
- Infertility Drugs
- Clomiphene citrate
- Sex hormones
- Gonadotropins
- Bromocriptine
- Cabergoline
- Imipramine
- Letrozole
- Metformin
- Infertility Devices
- Equipment
- Accessories
- Infertility Drugs
- By Gender
- Male
- Female
- By Country
- U.S.
- Canada
- By Type:
- Latin America
- By Type:
- By Gender
- By Country
- Europe
- By Type:
- By Gender
- By Country
- Asia Pacific
- By Type:
- By Gender
- By Country
- Middle East
- By Type:
- By Gender
- By Country
- Africa
- By Type:
- By Gender
- By Country
- North America
Have a Look at Related Research Insights:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837